Your Reliable Supplier of Natural Plant Extract Products in China!
|Place of Origin:||China|
|Minimum Order Quantity:||Negotiation|
|Packaging Details:||25kg/carbon drum; Tare: 2.8kg; diameter 50cm, height 40cm. 1kg/bag|
|Payment Terms:||L/C, D/A, D/P, T/T,PAYPAL|
|Name:||Andrographis Paniculate Extract||Ingredient:||Andrographolide|
|Type:||Herbal Plant Extract||Feature:||Anti Cancer|
pure herbal extracts,
pure herbal supplements
Herbal Plant Extract Anti-cancer Andrographolide of Andrographis Paniculate Extract
Plant Source of Andrographis Paniculate Extract:
Andrographis paniculata is widely cultivated in South of China, where it has been traditionally used to treat infections and some diseases. Mostly the leaves and roots were used for medicinal purposes. The whole plant is also used in some cases.
Andrographis paniculata grows erect to a height of 30–110 cm (12–43 in) in moist, shady places. The slender stem is dark green, squared in cross-section with longitudinal furrows and wings along the angles. The lance-shaped leaves have hairless blades measuring up to 8 cm (3.1 in) long by 2.5 cm (0.98 in). The small flowers are borne in spreading racemes. The fruit is a capsule around 2 cm (0.79 in) long and a few millimeters wide. It contains many yellow-brown seeds.
The Info of Andrographolide of Andrographis Paniculate Extract:
Andrographolide is a labdane diterpenoid that has been isolated from the stem and leaves of Andrographis paniculata.
CAS No.: 5508-58-7
Molecular Weight: 350.45
Basic Info of Andrographis Paniculate Extract:
|Product Name||Andrographis Paniculate Extract|
|Solvent Used||Water & Ethanol|
|Appearance||White / off white fine powder|
|Packing size||25kg/carbon drum, 1kg/bag|
Natural Ingredient, No synthetic part.
Non-GMO, Non-IR, Non-ETO, BSE Free.
|Shelf Life||2 years|
|Country of Origin||China|
|Sample Status||5g-10g free sample is available|
Applications of Andrographis Paniculate Extract:
Andrographolide treatment inhibited the in vitro proliferation of different tumor cell lines, representing various types of cancers. The compound exerts direct anticancer activity on cancer cells by cell-cycle arrest at G0/G1 phase through induction of cell-cycle inhibitory protein p27 and decreased expression of cyclin-dependent kinase 4 (CDK4).
Immunostimulatory activity of andrographolide is evidenced by increased proliferation of lymphocytes and production of interleukin-2. Andrographolide also enhanced the tumor necrosis factor-alpha production and CD marker expression, resulting in increased cytotoxic activity of lymphocytes against cancer cells, which may contribute for its indirect anticancer activity. The in vivo anticancer activity of the compound is further substantiated against B16F0 melanoma syngenic and HT-29 xenograft models. These results suggest that andrographolide is an interesting pharmacophore with anticancer and immunomodulatory activities and hence has the potential for being developed as a cancer therapeutic agent.
Contact Person: Ms. Chen